<DOC>
	<DOCNO>NCT00005049</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give intraperitoneal infusion may kill tumor cell . PURPOSE : Phase II trial study effectiveness intraperitoneal combination chemotherapy treat patient stage III ovarian epithelial cancer gastrointestinal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage III Ovarian Epithelial Cancer Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess tolerance complication consolidation therapy intraperitoneal floxuridine cisplatin and/or carboplatin patient stage III ovarian epithelial cancer gastrointestinal cancer peritoneal involvement . - Determine sit failure estimate time failure follow treatment regimen patient . OUTLINE : Patients stratify accord type residual disease second look laparotomy laparoscopy ( micro v great 0.5 cm v great 0.5 cm great 1 cm ) , CA-125 level ( elevated v normal day -7 ) . Patients receive intraperitoneal floxuridine day 1-3 follow intraperitoneal cisplatin and/or carboplatin day 3 . Treatment continue every 3 week 4-6 course absence disease progression unacceptable toxicity . Patients follow 4 6 week , 6 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A total 40 patient accrue study 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III ovarian epithelial cancer gastrointestinal cancer peritoneal involvement Patients ovarian cancer must complete first induction treatment platinum base regimen ( carboplatin and/or cisplatin ) clinical complete response time assessment study No ovarian cancer low malignant potential PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 3 time upper limit normal Renal : Creatinine clearance least 40 mL/min Other : No underlie medical psychiatric condition precludes inform consent PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Laparoscopy laparotomy require within 8 week study assess residual disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>